Bolniki z dobro prognozo, prikazano s stopnjo tumorja, Karnofskyjevim indeksom zmogljivosti (KPS - Karnofsky performance status) in starostjo, so imeli bolj poudarjeno korist, če je bil cetuksimab dodan kemoterapiji na osnovi platine.
Patients with a good prognosis as indicated by tumour stage, Karnofsky performance status (KPS) and age had a more pronounced benefit, when cetuximab was added to platinum-based chemotherapy.